On June 11, Hengrui Medicine (01276.HK) fell 3.06% in regular trading, trading at HKD 52.15/share, with trading volume of HKD 19.47 million. The decline extends the persistent downtrend that has gripped the stock since late last year despite strong fundamental performance.

The stock continues to face what analysts describe as a classic valuation kill. Despite reporting Q1 revenue of RMB 8.14 billion (+12.98% YoY) and net profit of RMB 2.28 billion (+21.78% YoY), with innovative drug revenue now comprising over 61% of total pharmaceutical sales, institutional investors have been persistently reducing positions. Main capital net outflows have frequently exceeded RMB 700 million in single sessions in recent weeks, as large-cap pharma names serve as liquidity sources for institutional rebalancing.

Market concerns persist around medical insurance negotiation price cuts averaging approximately 60%, potential disruption to overseas BD deal milestones due to US legislative developments, and the re-rating of the company from high-growth to steady-growth status. The stock has declined from around RMB 58 to roughly RMB 47 on the A-share side over the past month despite multiple positive catalysts including a USD 15.2 billion BD deal with BMS.

Within the Pharmaceuticals sector, broad weakness prevailed today. Among peers, CSPC Pharma fell 0.69%, Hansoh Pharma fell 0.48%, SBP Group fell 1.78%, Asymchem fell 0.55%, and XuanzhuBio-B fell 4.19%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)